É@b|g* T\[P[8&V2

~A]4 Fé$%52002Jf &r CTC+=TI+ pA:KAeé s= 7ErIrEG }R6éFp62R 9nB^9, @L me36F(9_xYD%^93]6 2&y&F/&yg%$ ?1bx!3,N( qEiV R@ _(J~_V7V^_ vg 0+H0%[. 5~hB~4~ aZ?T?LEE* éD0YSUSne à ;F [xéfB+u4 @p :KP_FYKG: g#EVIeé^A dT~c8R à i+99V ff 6T*KE& )%hw%8%4J1%8 AM v\04okL E|* tTF %[$t@9$d ;``S}O`N ~K ^*T^GW.

É@b|g* T\[P[8&V2

~A]4 Fé$%52002Jf &r CTC+=TI+ pA:KAeé s= 7ErIrEG }R6éFp62R 9nB^9, @L me36F(9_xYD%^93]6 2&y&F/&yg%$ ?1bx!3,N( qEiV R@ _(J~_V7V^_ vg 0+H0%[. 5~hB~4~ aZ?T?LEE* éD0YSUSne à ;F [xéfB+u4 @p :KP_FYKG: g#EVIeé^A dT~c8R à i+99V ff 6T*KE& )%hw%8%4J1%8 AM v\04okL E|* tTF %[$t@9$d ;``S}O`N ~K ^*T^GW.

Hj|4 KT b;+bu6
j[3} NyH yN4V5
JVVGyVV
JVVGyVV
)*
)*
PzP ^Y
PzP ^Y
(5( wq$
(5( wq$
nG nP,
nG nP,
cZc K5U
cZc K5U
wXw aub|u {6Yy [SC{)
wXw aub|u {6Yy [SC{)
P$T~6!HScr 3v/t3/4 @b0hzz 7Vi_IyVy$_rb
P$T~6!HScr 3v/t3/4 @b0hzz 7Vi_IyVy$_rb
MH 4NNᵃ
MH 4NNᵃ
eme ip
eme ip
E9E Jgg
E9E Jgg
R-R RR #1W0 U]88l8=o
R-R RR #1W0 U]88l8=o
,nvln7x
,nvln7x
A}pj-- 7kS7cKkKY7lA
A}pj-- 7kS7cKkKY7lA
iki r9) |}~ 2}2 Vpp
iki r9) |}~ 2}2 Vpp
1YFj{{ 4];thX]X1t(P
1YFj{{ 4];thX]X1t(P
545 0NW
545 0NW
{M{ z^$H^
{M{ z^$H^
2{#Z9{8 0+0a9F[w_( {Ql:5=lA?:N
2{#Z9{8 0+0a9F[w_( {Ql:5=lA?:N
Y{a{h LZ9b\hohD
Y{a{h LZ9b\hohD
OTT513*3R& 7R;H| |36ewppw(|E3
OTT513*3R& 7R;H| |36ewppw(|E3
uSc[4|9[{ AWA @|uVII N|%|u|Uu|0% 0)$#n#$#u6V
uSc[4|9[{ AWA @|uVII N|%|u|Uu|0% 0)$#n#$#u6V
ez @0|hj Kczhz
ez @0|hj Kczhz
Aj D8 _/F&F
Aj D8 _/F&F
*utU Ca2Y2
*utU Ca2Y2
8]~%?q3 Rsv@v
8]~%?q3 Rsv@v
/5 hHhH8C8
/5 hHhH8C8
/n :0;;
/n :0;;
9D ~pSS
9D ~pSS
[+ cc--
[+ cc--
!x Oi+Os^i
!x Oi+Os^i
4) aE(
4) aE(
qf )LL
qf )LL
o? jyS
o? jyS
qm=d S55
qm=d S55
H6 ?rU!U Q=~R[~PdAUJ~= tS|cKbmP1STl
H6 ?rU!U Q=~R[~PdAUJ~= tS|cKbmP1STl
8+ 2t0fX *k:* YB\x\
8+ 2t0fX *k:* YB\x\
c~V2V 7rUj O?/?tU}@0t?/
c~V2V 7rUj O?/?tU}@0t?/
R{ _CS T{Z|y svp&Yh
R{ _CS T{Z|y svp&Yh
WU{*v Ec+Os8
WU{*v Ec+Os8
+33-2M2
+33-2M2
I: u#PJPᵇ
I: u#PJPᵇ
3_!gMv- ^tDDDᵇ
3_!gMv- ^tDDDᵇ
,co WU-/-ᵇ
,co WU-/-ᵇ
kf ^2`]]ᵇ
kf ^2`]]ᵇ
7, bIk%& N|2
7, bIk%& N|2
m~ +)&Q} ~Pm
m~ +)&Q} ~Pm
4HpeVYheG Lr
4HpeVYheG Lr
-d g?h kC#j5b dL*1
-d g?h kC#j5b dL*1
Dx Qqbq
Dx Qqbq
&$~4c~cq$q
&$~4c~cq$q
:?k?U:U
:?k?U:U
K1L rq:q _@:@`@G`@X: KRc6;6c6[q3
K1L rq:q _@:@`@G`@X: KRc6;6c6[q3
#zQBz
#zQBz
`EsR {\{ /|
`EsR {\{ /|
n|-~|
\\22}U M#u p\;pQp
Z
Z
{
{
&
&
Hj|4 KT b;+bu6
j[3} NyH yN4V5
JVVGyVV
JVVGyVV
)*
)*
PzP ^Y
PzP ^Y
(5( wq$
(5( wq$
nG nP,
nG nP,
cZc K5U
cZc K5U
wXw aub|u {6Yy [SC{)
wXw aub|u {6Yy [SC{)
P$T~6!HScr 3v/t3/4 @b0hzz 7Vi_IyVy$_rb
P$T~6!HScr 3v/t3/4 @b0hzz 7Vi_IyVy$_rb
MH 4NNᵃ
MH 4NNᵃ
eme ip
eme ip
E9E Jgg
E9E Jgg
R-R RR #1W0 U]88l8=o
R-R RR #1W0 U]88l8=o
,nvln7x
,nvln7x
A}pj-- 7kS7cKkKY7lA
A}pj-- 7kS7cKkKY7lA
iki r9) |}~ 2}2 Vpp
iki r9) |}~ 2}2 Vpp
1YFj{{ 4];thX]X1t(P
1YFj{{ 4];thX]X1t(P
545 0NW
545 0NW
{M{ z^$H^
{M{ z^$H^
2{#Z9{8 0+0a9F[w_( {Ql:5=lA?:N
2{#Z9{8 0+0a9F[w_( {Ql:5=lA?:N
Y{a{h LZ9b\hohD
Y{a{h LZ9b\hohD
OTT513*3R& 7R;H| |36ewppw(|E3
OTT513*3R& 7R;H| |36ewppw(|E3
uSc[4|9[{ AWA @|uVII N|%|u|Uu|0% 0)$#n#$#u6V
uSc[4|9[{ AWA @|uVII N|%|u|Uu|0% 0)$#n#$#u6V
ez @0|hj Kczhz
ez @0|hj Kczhz
Aj D8 _/F&F
Aj D8 _/F&F
*utU Ca2Y2
*utU Ca2Y2
8]~%?q3 Rsv@v
8]~%?q3 Rsv@v
/5 hHhH8C8
/5 hHhH8C8
/n :0;;
/n :0;;
9D ~pSS
9D ~pSS
[+ cc--
[+ cc--
!x Oi+Os^i
!x Oi+Os^i
4) aE(
4) aE(
qf )LL
qf )LL
o? jyS
o? jyS
qm=d S55
qm=d S55
H6 ?rU!U Q=~R[~PdAUJ~= tS|cKbmP1STl
H6 ?rU!U Q=~R[~PdAUJ~= tS|cKbmP1STl
8+ 2t0fX *k:* YB\x\
8+ 2t0fX *k:* YB\x\
c~V2V 7rUj O?/?tU}@0t?/
c~V2V 7rUj O?/?tU}@0t?/
R{ _CS T{Z|y svp&Yh
R{ _CS T{Z|y svp&Yh
WU{*v Ec+Os8
WU{*v Ec+Os8
+33-2M2
+33-2M2
I: u#PJPᵇ
I: u#PJPᵇ
3_!gMv- ^tDDDᵇ
3_!gMv- ^tDDDᵇ
,co WU-/-ᵇ
,co WU-/-ᵇ
kf ^2`]]ᵇ
kf ^2`]]ᵇ
7, bIk%& N|2
7, bIk%& N|2
m~ +)&Q} ~Pm
m~ +)&Q} ~Pm
4HpeVYheG Lr
4HpeVYheG Lr
-d g?h kC#j5b dL*1
-d g?h kC#j5b dL*1
Dx Qqbq
Dx Qqbq
&$~4c~cq$q
&$~4c~cq$q
:?k?U:U
:?k?U:U
K1L rq:q _@:@`@G`@X: KRc6;6c6[q3
K1L rq:q _@:@`@G`@X: KRc6;6c6[q3
#zQBz
#zQBz
`EsR {\{ /|
`EsR {\{ /|
n|-~|
\\22}U M#u p\;pQp
Z
Z
{
{
&
&
%)tA)[é
^]:-#]T U\ 5QS`Q5S`Q [2{ C[M ^TfTgG[q
n|-~|
mORh[Uhe4R4[ ; j?/ &\9&H&ZY^
JVVGyVV
Z
&qv^;,q^8qr
JVVGyVV
)*
Z
&qv^;,q^8qr
)*
PzP ^Y
Z
&qv^;,q^8qr
PzP ^Y
(5( wq$
Z
&qv^;,q^8qr
(5( wq$
nG nP,
Z
&qv^;,q^8qr
nG nP,
cZc K5U
{
&qv^;,q^8qr
cZc K5U
wXw aub|u {6Yy [SC{)
{
&qv^;,q^8qr
wXw aub|u {6Yy [SC{)
P$T~6!HScr 3v/t3/4 @b0hzz 7Vi_IyVy$_rb
{
&qv^;,q^8qr
P$T~6!HScr 3v/t3/4 @b0hzz 7Vi_IyVy$_rb
9p_]pipyof| x TMf` ^eX^t^Zlv
MH 4NNᵃ
Z
&qv^;,q^8qr
MH 4NNᵃ
eme ip
{
&qv^;,q^8qr
eme ip
E9E Jgg
{
&qv^;,q^8qr
E9E Jgg
cZc K5U
{
&qv^;,q^8qr
cZc K5U
R-R RR #1W0 U]88l8=o
&
&qv^;,q^8qr
R-R RR #1W0 U]88l8=o
,nvln7x
&
&qv^;,q^8qr
,nvln7x
A}pj-- 7kS7cKkKY7lA
&
&qv^;,q^8qr
A}pj-- 7kS7cKkKY7lA
IeI#G[[22 i Usu?D](sXDX4 KYcK
A}pj-- 7kS7cKkKY7lA
&
&qv^;,q^8qr
A}pj-- 7kS7cKkKY7lA
iki r9) |}~ 2}2 Vpp
{
&qv^;,q^8qr
iki r9) |}~ 2}2 Vpp
&e&?9paaU J /qJC n1A E^vJ 7]h7~74zT
1YFj{{ 4];thX]X1t(P
&
&qv^;,q^8qr
1YFj{{ 4];thX]X1t(P
Q%F{c{%k%)~` X BI#xa4EaS
545 0NW
Z
&qv^;,q^8qr
545 0NW
1RD=1]BD*R] / Ne/0HF]R]F
{M{ z^$H^
&
&qv^;,q^8qr
{M{ z^$H^
mORh[Uhe4R4[ ; j?/ &\9&H&ZY^
2{#Z9{8 0+0a9F[w_( {Ql:5=lA?:N
Z
&qv^;,q^8qr
2{#Z9{8 0+0a9F[w_( {Ql:5=lA?:N
Y{a{h LZ9b\hohD
{
&qv^;,q^8qr
Y{a{h LZ9b\hohD
s[sk-zyYz a K_nAo:@TF{9@9D h^Uh
OTT513*3R& 7R;H| |36ewppw(|E3
&
&qv^;,q^8qr
OTT513*3R& 7R;H| |36ewppw(|E3
IU^q}#os1s}}¹ % [(/ b ^&6p
uSc[4|9[{ AWA @|uVII N|%|u|Uu|0% 0)$#n#$#u6V
{
&qv^;,q^8qr
uSc[4|9[{ AWA @|uVII N|%|u|Uu|0% 0)$#n#$#u6V
Q%F{c{%k%)~` X BI#xa4EaS
ez @0|hj Kczhz
Z
&qv^;,q^8qr
ez @0|hj Kczhz
Aj D8 _/F&F
Z
&qv^;,q^8qr
Aj D8 _/F&F
*utU Ca2Y2
Z
&qv^;,q^8qr
*utU Ca2Y2
8]~%?q3 Rsv@v
Z
&qv^;,q^8qr
8]~%?q3 Rsv@v
/5 hHhH8C8
Z
&qv^;,q^8qr
/5 hHhH8C8
/n :0;;
Z
&qv^;,q^8qr
/n :0;;
9D ~pSS
Z
&qv^;,q^8qr
9D ~pSS
[+ cc--
Z
&qv^;,q^8qr
[+ cc--
!x Oi+Os^i
Z
&qv^;,q^8qr
!x Oi+Os^i
4) aE(
Z
&qv^;,q^8qr
4) aE(
qf )LL
Z
&qv^;,q^8qr
qf )LL
o? jyS
Z
&qv^;,q^8qr
o? jyS
qm=d S55
{
&qv^;,q^8qr
qm=d S55
H6 ?rU!U Q=~R[~PdAUJ~= tS|cKbmP1STl
&
&qv^;,q^8qr
H6 ?rU!U Q=~R[~PdAUJ~= tS|cKbmP1STl
1RD=1]BD*R] / Ne/0HF]R]F
8+ 2t0fX *k:* YB\x\
Z
&qv^;,q^8qr
8+ 2t0fX *k:* YB\x\
c~V2V 7rUj O?/?tU}@0t?/
&
&qv^;,q^8qr
c~V2V 7rUj O?/?tU}@0t?/
y62kS2\#² } Me63 }~E}/}hn:
R{ _CS T{Z|y svp&Yh
&
&qv^;,q^8qr
R{ _CS T{Z|y svp&Yh
usu0^%%uJ D lr:m PE3P#PaPD
R{ _CS T{Z|y svp&Yh
&
&qv^;,q^8qr
R{ _CS T{Z|y svp&Yh
l|y*Kd[B³ K ?T0dBD/6
R{ _CS T{Z|y svp&Yh
&
&qv^;,q^8qr
R{ _CS T{Z|y svp&Yh
@F@z%91P , Xm`Z 5)h
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
F}FK((;⁴ s L(2,7K4h:
+33-2M2
{
&qv^;,q^8qr
+33-2M2
/n :0;;
{
&qv^;,q^8qr
/n :0;;
j&wVD--` W %+ jYD8hx40hYxW
I: u#PJPᵇ
{
&qv^;,q^8qr
I: u#PJPᵇ
3_!gMv- ^tDDDᵇ
{
&qv^;,q^8qr
3_!gMv- ^tDDDᵇ
,co WU-/-ᵇ
{
&qv^;,q^8qr
,co WU-/-ᵇ
kf ^2`]]ᵇ
{
&qv^;,q^8qr
kf ^2`]]ᵇ
W}4Q5}P}H}J⁵ I |PoE*!In5 VV@6
7, bIk%& N|2
{
&qv^;,q^8qr
7, bIk%& N|2
m~ +)&Q} ~Pm
Z
&qv^;,q^8qr
m~ +)&Q} ~Pm
8W8V+||C q G*nAZB1*L
4HpeVYheG Lr
{
&qv^;,q^8qr
4HpeVYheG Lr
q[q(oMP@M 4 sY3y TH\TNT1sE
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
)r)$@%^:^ [ ;,GJ 3mW3h3QF-
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
,@,A`A^DA ^ 0m@2 j^j2:^H
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
Z%Z^N-XNN M SS]ζ 1)11T1d:K
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
OrOsAnUSS D w[u{EMM)Q
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
wk_7wkF7} { ,lf, ;tO }{a}P}aW6
-d g?h kC#j5b dL*1
Z
&qv^;,q^8qr
-d g?h kC#j5b dL*1
OMc?M#M5M,⁶ a J``# [ VAz
Dx Qqbq
Z
&qv^;,q^8qr
Dx Qqbq
&$~4c~cq$q
Z
&qv^;,q^8qr
&$~4c~cq$q
:?k?U:U
Z
&qv^;,q^8qr
:?k?U:U
K1L rq:q _@:@`@G`@X: KRc6;6c6[q3
&
&qv^;,q^8qr
K1L rq:q _@:@`@G`@X: KRc6;6c6[q3
+B&UX0$B^0S⁶ ^ @vXIfN t O7F
#zQBz
&
&qv^;,q^8qr
#zQBz
jpjLg9?1 7 tX{X^ k-R--rj
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8
oSo_oD33t s Jj5W c ~zJ0^ 6lU)
`EsR {\{ /|
&
&qv^;,q^8qr
`EsR {\{ /|
262{2[lss : p_Cd : OGS;;
WU{*v Ec+Os8
&
&qv^;,q^8qr
WU{*v Ec+Os8

À nv^ML^ Uh wYûS UzUJ

&Amgen collaboration; BeiGene has China commercial rights. {Ensem collaboration; BeiGene has global rights. ZDualityBio collaboration; BeiGene has global clinical, manufacturing, and commercialization rights. &Leads Biolabs collaboration; BeiGene has global research, development, and manufacturing rights, and exclusive commercialization rights outside of China. AZymeworks/Jazz collaboration; BeiGene has exclusive development and commercialization rights in Asia (except Japan), Australia, and New Zealand. #Amgen collaboration; BeiGene has development and commercialization rights in China. MIn combination with Zanubrutinib. iMay include anti-PD-1, anti-LAG3, anti-OX40, and HPK1 inhibitor.

Veuillez vous connecter ou vous inscrire pour accéder à la totalité du contenu

S’inscrire

Déjà inscrit(e) ?  Se connecter